Rapid and functional evaluation of virus-neutralizing antibodies using multi-parametric live cell analysis

Join us on Wednesday, August 26, to learn about an alternative assay that aims to identify virus-neutralizing antibodies in as little as five hours

5 Aug 2020

Diane Li

Assistant Editor

Dr. Brandon Lamarche, Principal Scientist, Head of xCELLigence Application Development, Agilent Technologies

Current methods for screening virus-neutralizing antibodies, such as the canonical plaque reduction neutralization test, require multiple handling steps and numerous days to complete. Using gold-electrode biosensors and combined imaging, the xCELLigence family of instruments continuously and non-invasively monitor virus-induced changes in host cell number, size, attachment strength, and barrier function.

In this upcoming webinar, Dr. Brandon Lamarche from Agilent Technologies, will highlight an alternative assay that promises to identify virus-neutralizing antibodies and yield an abundance of quantitative kinetic information in as little as five hours.

Learning objectives:

Discover a more efficient method to screen virus-neutralizing antibodies to accelerate therapeutic antibody discovery
Learn how to quantitatively evaluate antibody efficacy by EC50 and identify different neutralizing mechanisms of action with the xCELLigence RTCA eSight
Tips for xCELLigence RTCA eSight assay design and optimization, and the advantages of combining real-time impedance and live-cell imaging

Who should attend

Scientists working in infectious disease, virology, therapeutic antibody research, including lab managers, professors, research scientists, graduate students

Certificate of attendance

All webinar participants can request a certificate of attendance and a learning outcomes summary document for continuing education purposes.

The live webinar takes place on Wednesday, August 26, at: